A Phase 2 interventional study of Niraparib and Bevacizumab in Ovarian Neoplasms, sponsored by Tesaro, Inc.. Completed at 29 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.
Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 12th largest by enrollment, is one of 4 that started in 2017, is one of 18 in phase 2, and was the 11th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
University of Miami · Sites in United States, Nigeria
Ages 18+ · Women only
MedSIR · Sites in Spain
Ages 18+ · Women only
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+ · Women only
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+ · Women only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Women only
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 22 · Phase 3 7 · Phase 4 5
First in 2008; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 41 across the 44 interventional studies. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tesaro, Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
31 studies in Ovarian Neoplasms by GlaxoSmithKline: 5 open now, 7 under way, 5 of them phase 3. Of 22 finished, 16 (73%) have results posted.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 14th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2017, is one of 15 in phase 2, and was the 21st registered.
GlaxoSmithKline’s Ovarian Neoplasms studies by the year they started, since 1997.
2 of the studies testing niraparib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
| NCT06594679Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoA Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) | 2027-03-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies testing niraparib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
Niraparib is an oral inhibitor of poly adenosine diphosphate-ribose polymerase (PARP)-1 and PARP-2. This study will evaluate safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in participants with advanced (stage IIIB-IV) ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following front-line platinum-based chemotherapy with bevacizumab. Eligible participants who achieve complete response (CR), partial response (PR), or no evidence of disease (NED) following treatment with platinum-based chemotherapy in addition to bevacizumab will be enrolled in the study and will receive maintenance treatment with niraparib (for up to 3 years) combined with bevacizumab (for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of the approximately 5 months of bevacizumab received with chemotherapy) or until disease progression, unacceptable toxicity, participant withdrawal, Investigator's decision, or death, whichever comes first. Participants who have not progressed after 3 years of niraparib maintenance treatment may continue with niraparib beyond 3 years if they are benefiting from treatment, upon consultation with Sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle (84-day cycle after amendment 2). On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
Drug: Niraparib · Biological: Bevacizumab
Niraparib will be administered orally once a day continuously throughout each 21 day cycle (84-day cycle after amendment 2). The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count. Participants with a Baseline actual body weight of greater than equal to (\>=) 77 kg and Baseline platelet count of \>=150,000/ microliter (μL) will take 300 mg/day (3X100mg) at each dose administration. Participants with a Baseline actual body weight of less than (\<) 77 kg and/or Baseline platelet count of \<150,000/μL will take 200 mg (2X100 mg) at each dose administration.
Also known as: ZEJULA
Maintenance bevacizumab 15 mg/kg will be administered via a 30-minute IV infusion on Day 1 of every 21-day cycle in the absence of progressive disease (PD), unacceptable toxicity, participant withdrawal, Investigator's decision, or death. Bevacizumab will be administered for up to 10 months during the maintenance phase or up to a total of 15 months inclusive of approximately 5 months of bevacizumab received with chemotherapy.
Also known as: Avastin
Progression Free Survival (PFS) Rate
PFS rate at 18 months is defined as the percentage of participants who have not progressed or died within 18 months after niraparib combined with bevacizumab treatment initiation. Progression was assessed by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 criteria per Investigator assessment and defined as a 20 percent (%) increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions. Survival rate is the percentage of participants without progression assessed by RECIST v1.1 or death by the landmark timepoint. Confidence intervals was constructed using exact method.
Time frame: At 18 months
Progression Free Survival (PFS) by RECIST v 1.1
PFS was defined as the time from treatment initiation with niraparib combined with bevacizumab to the earlier date of assessment of progression, as assessed by RECIST v1.1 criteria, based on Investigator assessment, or death by any cause in the absence of progression.
Time frame: Up to end of study (approximately 79 months)
Overall Survival (OS)
OS was defined as the date of initiation of niraparib treatment in combination with bevacizumab to the date of death by any cause.
Time frame: Up to end of study (approximately 79 months)
RECIST or Cancer Antigen (CA)-125 Progression Free Survival
RECIST or CA-125 progression-free survival is defined as the time from initiation of niraparib treatment in combination with bevacizumab to the earliest date of progression assessed by RECIST v1.1 or CA-125 progression or death by any cause. CA-125 progression is defined as participants with elevated CA-125 pretreatment and normalization of CA-125 that must show evidence of CA-125 ≥ 2 × upper limit of normal (ULN) on 2 occasions at least 1 week apart OR elevated CA-125 pretreatment that never normalizes and must show evidence of CA-125 ≥ 2 × the nadir value on 2 occasions at least 1 week apart OR elevated CA-125 in the normal range pretreatment that must show evidence of CA-125 ≥ 2 × ULN on 2 occasions at least 1 week apart.
Time frame: Up to end of study (approximately 79 months)
Change From Baseline (CFB) in Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI)
FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from "not at all" (0) to "very much" (4). FOSI score was calculated as sum of item scores multiplied by 8 divided by number of items answered. The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1), Cycles 3, 5, 7, 9, 13, 17, 21, 25, 29 (Each Cycle was of 21 days) and end of treatment (70 months)
Time to First Subsequent Therapy (TFST)
TFST was defined as the date of initiation of niraparib treatment in combination with bevacizumab treatment in the current study to the start date of the first subsequent anticancer therapy.
Time frame: Up to end of study (approximately 79 months)
Time to Second Subsequent Therapy (TSST)
TSST was defined as the date of initiation of treatment of niraparib in combination with bevacizumab treatment in the current study to the start date of the second subsequent anticancer therapy.
Time frame: Up to end of study (approximately 79 months)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Non-serious TEAEs and Treatment-emergent Serious Adverse Events (TESAEs)
Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAEs is any AE that occurred for the first time after at least 1 dose of study treatment administration and until treatment duration. TEAEs which were not serious were considered as non-serious TEAEs. TESAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. Percentages are rounded off to the nearest decimal point.
Time frame: Up to end of treatment (70 months)
Number of Participants With TEAEs Leading to Niraparib Treatment Discontinuation
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.
Time frame: Up to end of treatment (70 months)
Number of Participants With TEAEs Leading to Niraparib Dose Reductions
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.
Time frame: Up to end of treatment (70 months)
Number of Participants With AEs of Special Interest (AESI)
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs of scientific and medical concern related to the treatment were monitored, and rapidly communicated by investigator to sponsor. AEs were coded using the MedDRA coding system.
Time frame: Up to end of treatment (70 months)
Change From Baseline (CFB) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Pulse Rate
Pulse Rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Temperature
Temperature was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Number of Participants Who Used Concomitant Medications
Any permitted concomitant medication(s), including non-prescription medication(s) and herbal product(s), taken during the study were recorded.
Time frame: Up to end of treatment (70 months)
Change From Baseline (CFB) in Hematology Parameters: Basophils, Eosinophil, Leukocytes, Platelets, Lymphocytes, Monocytes and Neutrophils
Blood samples were collected for the assessment of change from Baseline in hematology parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Hematology Parameter: Hemoglobin (Hb)
Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)
Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Urea Nitrogen, Glucose, Calcium, Chloride, Sodium, Magnesium and Potassium
Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Bilirubin and Creatinine
Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Albumin and Protein
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
Change From Baseline (CFB) in Clinical Chemistry Parameters: Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
Time frame: Baseline (Day 1) and end of treatment (70 months)
| Milestone | Niraparib + Bevacizumab |
|---|---|
| Started | 105 |
| Completed | 70 |
| Not completed | 35 |
| Withdrew: Sponsor decision | 35 |
PFS rate at 18 months is defined as the percentage of participants who have not progressed or died within 18 months after niraparib combined with bevacizumab treatment initiation. Progression was assessed by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 criteria per Investigator assessment and defined as a 20 percent (%) increase in the sum of the diameter of target lesions or unequivocal progression of existing non-target lesions. Survival rate is the percentage of participants without progression assessed by RECIST v1.1 or death by the landmark timepoint. Confidence intervals was constructed using exact method.
| Percentage of participants | Niraparib + Bevacizumab |
|---|---|
| Progression Free Survival (PFS) Rate | 62 (51.9 to 71.2) |
PFS was defined as the time from treatment initiation with niraparib combined with bevacizumab to the earlier date of assessment of progression, as assessed by RECIST v1.1 criteria, based on Investigator assessment, or death by any cause in the absence of progression.
| Months | Niraparib + Bevacizumab |
|---|---|
| Progression Free Survival (PFS) by RECIST v 1.1 | 19.6 (16.56 to 25.07) |
OS was defined as the date of initiation of niraparib treatment in combination with bevacizumab to the date of death by any cause.
| Months | Niraparib + Bevacizumab |
|---|---|
| Overall Survival (OS) | 61.1 (44.88 to NA) |
RECIST or CA-125 progression-free survival is defined as the time from initiation of niraparib treatment in combination with bevacizumab to the earliest date of progression assessed by RECIST v1.1 or CA-125 progression or death by any cause. CA-125 progression is defined as participants with elevated CA-125 pretreatment and normalization of CA-125 that must show evidence of CA-125 ≥ 2 × upper limit of normal (ULN) on 2 occasions at least 1 week apart OR elevated CA-125 pretreatment that never normalizes and must show evidence of CA-125 ≥ 2 × the nadir value on 2 occasions at least 1 week apart OR elevated CA-125 in the normal range pretreatment that must show evidence of CA-125 ≥ 2 × ULN on 2 occasions at least 1 week apart.
| Months | Niraparib + Bevacizumab |
|---|---|
| RECIST or Cancer Antigen (CA)-125 Progression Free Survival | 16.9 (13.27 to 22.05) |
FOSI is a validated, 8-item measure of symptom response to treatment for ovarian cancer. Participants responded to their symptom experience over the past 7 days using a 5-point Likert scale scored from "not at all" (0) to "very much" (4). FOSI score was calculated as sum of item scores multiplied by 8 divided by number of items answered. The FOSI score ranged from 0 (severely symptomatic) to 32 (asymptomatic). A higher score indicated a better quality of life (QoL). Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Scores on scale | Niraparib + Bevacizumab |
|---|---|
| Baseline (Day 1) | 25.7 ± 3.79 |
| CFB to Cycle 3 | -1.4 ± 4.30 |
| CFB to Cycle 5 | -1.7 ± 3.89 |
| CFB to Cycle 7 | -0.3 ± 3.09 |
| CFB to Cycle 9 | -1.1 ± 3.74 |
| CFB to Cycle 13 | -1.1 ± 4.25 |
| CFB to Cycle 17 | -0.7 ± 3.39 |
| CFB to Cycle 21 | -0.6 ± 3.77 |
| CFB to Cycle 25 | 0.1 ± 3.73 |
| CFB to Cycle 29 | 0.7 ± 3.40 |
| CFB to End of Treatment (70 months) | -2.0 ± 5.21 |
TFST was defined as the date of initiation of niraparib treatment in combination with bevacizumab treatment in the current study to the start date of the first subsequent anticancer therapy.
| Months | Niraparib + Bevacizumab |
|---|---|
| Time to First Subsequent Therapy (TFST) | 17.5 (14.55 to 20.73) |
TSST was defined as the date of initiation of treatment of niraparib in combination with bevacizumab treatment in the current study to the start date of the second subsequent anticancer therapy.
| Months | Niraparib + Bevacizumab |
|---|---|
| Time to Second Subsequent Therapy (TSST) | 38.6 (30.55 to 55.85) |
Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAEs is any AE that occurred for the first time after at least 1 dose of study treatment administration and until treatment duration. TEAEs which were not serious were considered as non-serious TEAEs. TESAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. Percentages are rounded off to the nearest decimal point.
| Percentage of participants | Niraparib + Bevacizumab |
|---|---|
| TEAEs | 100 |
| Non-serious TEAEs | 100 |
| TESAEs | 30.5 |
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.
| Participants | Niraparib + Bevacizumab |
|---|---|
| Number of Participants With TEAEs Leading to Niraparib Treatment Discontinuation | 46 |
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. TEAE is any AE that occurred for the first time after at least 1 dose of study treatment administration. AEs were coded using the MedDRA coding system.
| Participants | Niraparib + Bevacizumab |
|---|---|
| Number of Participants With TEAEs Leading to Niraparib Dose Reductions | 81 |
AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AESIs of scientific and medical concern related to the treatment were monitored, and rapidly communicated by investigator to sponsor. AEs were coded using the MedDRA coding system.
| Participants | Niraparib + Bevacizumab |
|---|---|
| New malignancies other than Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) | 4 |
| MDS/AML Event | 2 |
Blood pressures (DBP and SBP) were measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Millimeter of mercury (mmHg) | Niraparib + Bevacizumab |
|---|---|
| SBP: Baseline (Day 1) | 129.7 ± 15.87 |
| SBP: CFB to End of Treatment (70 months) | 2.8 ± 21.70 |
| DBP: Baseline (Day 1) | 78.2 ± 9.30 |
| DBP: CFB to End of Treatment (70 months) | 0.3 ± 11.17 |
Pulse Rate was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Beats/minute | Niraparib + Bevacizumab |
|---|---|
| Baseline (Day 1) | 80.6 ± 11.40 |
| CFB to End of Treatment (70 months) | 4.3 ± 13.12 |
Temperature was measured after resting for at least 5 minutes in a supine or semi-recumbent position. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Celsius | Niraparib + Bevacizumab |
|---|---|
| Baseline (Day 1) | 36.59 ± 0.297 |
| CFB to End of Treatment (70 months) | -0.01 ± 0.439 |
Any permitted concomitant medication(s), including non-prescription medication(s) and herbal product(s), taken during the study were recorded.
| Participants | Niraparib + Bevacizumab |
|---|---|
| Number of Participants Who Used Concomitant Medications | 100 |
Blood samples were collected for the assessment of change from Baseline in hematology parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Giga cells per liter (10^9 cells/L) | Niraparib + Bevacizumab |
|---|---|
| Basophils: Baseline (Day 1) | 0.025 ± 0.0320 |
| Basophils: CFB to End of Treatment (70 months) | 0.008 ± 0.0385 |
| Eosinophil: Baseline (Day 1) | 0.168 ± 0.3071 |
| Eosinophil: CFB to End of Treatment (70 months) | -0.028 ± 0.3245 |
| Leukocytes: Baseline (Day 1) | 5.523 ± 1.5398 |
| Leukocytes: CFB to End of Treatment (70 months) | 0.660 ± 3.9571 |
| Platelets: Baseline (Day 1) | 219.810 ± 79.5186 |
| Platelets: CFB to End of Treatment (70 months) | -6.585 ± 74.0943 |
| Lymphocytes: Baseline (Day 1) | 1.694 ± 0.6216 |
| Lymphocytes: CFB to End of Treatment (70 months) | 0.152 ± 2.1904 |
| Monocytes: Baseline (Day 1) | 0.492 ± 0.2137 |
| Monocytes: CFB to End of Treatment (70 months) | 0.007 ± 0.1819 |
| Neutrophils: Baseline (Day 1) | 3.135 ± 1.1369 |
| Neutrophils: CFB to End of Treatment (70 months) | 0.197 ± 1.6063 |
Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Grams per liter (g/L) | Niraparib + Bevacizumab |
|---|---|
| Baseline (Day 1) | 116.800 ± 10.0234 |
| CFB to End of Treatment (70 months) | 4.787 ± 14.4303 |
Blood samples were collected for the assessment of change from Baseline in hematology parameter. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Femtoliters (fL) | Niraparib + Bevacizumab |
|---|---|
| Baseline (Day 1) | 97.560 ± 7.0779 |
| CFB to End of Treatment (70 months) | 0.093 ± 5.4536 |
Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Millimoles per liter (mmol/L) | Niraparib + Bevacizumab |
|---|---|
| Urea Nitrogen: Baseline (Day 1) | 5.681 ± 1.7222 |
| Urea Nitrogen: CFB to End of Treatment (70 months) | 0.375 ± 2.1948 |
| Glucose: Baseline (Day 1) | 5.996 ± 2.3156 |
| Glucose: CFB to End of Treatment (70 months) | -0.073 ± 2.8001 |
| Calcium: Baseline (Day 1) | 2.377 ± 0.0872 |
| Calcium: CFB to End of Treatment (70 months) | 0.018 ± 0.1005 |
| Chloride: Baseline (Day 1) | 102.747 ± 2.9885 |
| Chloride: CFB to End of Treatment (70 months) | -0.536 ± 3.4272 |
| Sodium: Baseline (Day 1) | 139.467 ± 2.8184 |
| Sodium: CFB to End of Treatment (70 months) | -0.298 ± 2.7192 |
| Magnesium: Baseline (Day 1) | 0.764 ± 0.1024 |
| Magnesium: CFB to End of Treatment (70 months) | 0.017 ± 0.0977 |
| Potassium: Baseline (Day 1) | 4.206 ± 0.3860 |
| Potassium: CFB to End of Treatment (70 months) | 0.031 ± 0.4891 |
Blood samples were collected for the assessment of change from Baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Micromoles per liter (umol/L) | Niraparib + Bevacizumab |
|---|---|
| Bilirubin: Baseline (Day 1) | 6.242 ± 2.8546 |
| Bilirubin: CFB to End of Treatment (70 months) | 1.168 ± 3.2660 |
| Creatinine: Baseline (Day 1) | 65.577 ± 16.3865 |
| Creatinine: CFB to End of Treatment (70 months) | 9.339 ± 16.4405 |
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| Grams per liter (g/L) | Niraparib + Bevacizumab |
|---|---|
| Albumin: Baseline (Day 1) | 41.629 ± 3.3748 |
| Albumin: CFB to End of Treatment (70 months) | 0.926 ± 3.1902 |
| Protein: Baseline (Day 1) | 70.619 ± 5.0676 |
| Protein: CFB to End of Treatment (70 months) | 0.309 ± 4.5744 |
Blood samples were collected for the assessment of change from baseline in clinical chemistry parameters. Baseline (Day 1) is defined as the most recent measurement prior to the first administration of study drug (including Cycle 1 Day 1).
| International units per Liter (IU/L) | Niraparib + Bevacizumab |
|---|---|
| AST: Baseline (Day 1) | 24.619 ± 12.0043 |
| AST: CFB to End of Treatment (70 months) | 5.117 ± 20.0863 |
| ALT: Baseline (Day 1) | 23.590 ± 13.4241 |
| ALT: CFB to End of Treatment (70 months) | 4.362 ± 19.3484 |
Collected over All-cause mortality was collected up to approximately 79 months (end of study) and treatment emergent non-serious adverse events and serious adverse events were collected up to 70 months (end of treatment).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Niraparib + Bevacizumab | 56/105 (53.3%) | 32/105 (30.5%) | 105/105 (100%) |
| Event | Niraparib + Bevacizumab |
|---|---|
| Platelet count decreasedInvestigations | 8/105 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/105 |
| Small intestinal obstructionGastrointestinal disorders | 2/105 |
| Chest painGeneral disorders | 2/105 |
| HypertensionVascular disorders | 2/105 |
| AnaemiaBlood and lymphatic system disorders | 1/105 |
| PancytopeniaBlood and lymphatic system disorders | 1/105 |
| DysphagiaGastrointestinal disorders | 1/105 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/105 |
| PyrexiaGeneral disorders | 1/105 |
| Event | Niraparib + Bevacizumab |
|---|---|
| FatigueGeneral disorders | 72/105 |
| NauseaGastrointestinal disorders | 65/105 |
| HeadacheNervous system disorders | 59/105 |
| HypertensionVascular disorders | 57/105 |
| AnaemiaBlood and lymphatic system disorders | 55/105 |
| ProteinuriaRenal and urinary disorders | 43/105 |
| Platelet count decreasedInvestigations | 42/105 |
| ConstipationGastrointestinal disorders | 40/105 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 38/105 |
| ThrombocytopeniaBlood and lymphatic system disorders | 36/105 |
| Age, Continuous(Years) | Niraparib + Bevacizumab |
|---|---|
| Mean | 59.7 ± 10.33 |
| Sex: Female, Male(Participants) | Niraparib + Bevacizumab |
|---|---|
| Female | 105 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Niraparib + Bevacizumab |
|---|---|
| White | 91 |
| Black or African American | 4 |
| Asian | 3 |
| American Indian or Alaska Native | 1 |
| Unknown | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Dec 2020, 36 months.
Results were first posted in Jan 2022, 1 year after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 36 months is close to that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niraparib · Bevacizumab